Entities / Company
Sage Therapeutics (United States).
company in Cambridge, Massachusetts, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Gone quiet
No new reports in 90+ days-
Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.Well supported4 reports1 development inside
-
Sage Therapeutics received a rating upgrade from Zacks Rank based on positive changes in its earnings outlook.Speculative1 report
-
The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.Well supported6 reports
No events began in the chosen period. Widen it, or reset.
Connections
The 2 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Supernus Pharmaceuticals (United States) Structural
Supernus Pharmaceuticals acquired Sage Therapeutics in a deal worth up to $795 million, establishing a parent-subsidiary relationship.
-
Biogen Operational
The companies maintain an ongoing operational partnership for Zurzuvae commercialization while simultaneously engaging in strategic competition and M&A attempts.
History
Events by the month they beganJune 2026
3 events- Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.
- Sage Therapeutics received a rating upgrade from Zacks Rank based on positive changes in its earnings outlook.
- The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.